-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 27, Merck announced that the Board of Directors unanimously elected Robert M.
Davis as Chairman (Chairman) of the Board of Directors, effective
December 1, 2022.
He will succeed Kenneth C.
Frazier, who is scheduled to retire on November 30, 2022, after his long career at Merck began in 1992
.
From 2011 to 2021, Frazier served as the company's president and CEO for 10 years
.
He has been a director of Merck since January 2011 and chairman of the board of
directors since December 2011.
DavisKenneth C.
Frazier
Robert M.
Davis
Davis
Davis, currently President and Chief Executive Officer, became President of Merck in April 2021 and was appointed CEO and member of the Board of Directors of
Merck in July 2021.
Kenneth C.
Frazier
Frazier
"Merck is driven by the talent, passion and commitment of thousands of people around the world united by a common goal: to harness the power of science to solve the world's most pressing health challenges
," Frazier said.
I feel very happy and honored to be part of the Merck team, and I will always be grateful to my colleagues for their hard work leading the company's many important achievements
.
I would also like to thank Merck's Board of Directors for its expertise and support
over the years.
With Rob Davis as the new chairman, I am confident that the Board will continue to help the company in a way that will allow the company to succeed in the
competition and remain committed to its mission.
" ”
"On behalf of Merck management and our colleagues around the world, I would like to express our deepest gratitude
to Ken for his countless contributions and indelible impact on our company and global health," Davis said.
During his tenure, Ken has led with strong conviction, advocated for patients, and created meaningful value
for stakeholders.
He has been a model
of goal-driven leadership, vision and courage.
I am honored to lead Merck as Chairman and CEO as we continue to build on his profound achievements
.
" ”
About Robert M.
Davis
Davis
Robert M.
Davis is CEO and President of Merck & Co
.
Previously, Rob served as President of Merck & Co.
, Ltd.
, where he was responsible for the company's operating divisions – Human Health, Animal Health, Manufacturing and Merck Research Laboratories
.
Prior to that, he served as Executive Vice President of Global Services and Corporate Chief Financial Officer
.
Rob joined the company in 2014 as Chief Financial Officer and is responsible for real estate operations, corporate strategy and business development
.
In 2016, his responsibilities expanded to include responsibilities in information technology and procurement, forming Global Services
.
He served as President in April 2021 and Chief Executive Officer and Board Member on
July 1, 2021.
Prior to joining Merck, Rob was Vice President and President of
Baxter's Medical Products business.
During his tenure at Baxter, he also held several other positions, including president, chief financial officer and treasurer
of Baxter's nephrology business.
Prior to joining Baxter in 2004, Rob spent 14 years
with Eli Lilly.
Rob is a member of the Board of Directors of Duke Energy Corporation and is also the Chairman of its Finance and Risk Management Committee and a member of the Corporate Governance Committee
.
In addition, Rob is a board member of Project Hope, a nonprofit dedicated to empowering healthcare workers to provide expert care
when and where they need it most.
Rob received his J.
D.
from Northwestern University School of Law, an MBA from Northwestern University's Kellogg Graduate School of Management, and a B.
A.
in Finance from the University of Miami.
